|
Pronunciation |
|
(sul
fa SEE ta mide SOW dee um &
pred NIS oh lone) |
|
|
U.S. Brand
Names |
|
AK-Cide® Ophthalmic; Blephamide®
Ophthalmic; Cetapred® Ophthalmic; Isopto® Cetapred®
Ophthalmic; Metimyd® Ophthalmic; Vasocidin®
Ophthalmic |
|
|
Generic
Available |
|
Yes |
|
|
Synonyms |
|
prednisolone and sulfacetamide |
|
|
Pharmacological Index |
|
Antibiotic/Corticosteroid, Ophthalmic |
|
|
Use |
|
Steroid-responsive inflammatory ocular conditions where infection is present
or there is a risk of infection; ophthalmic suspension may be used as an otic
preparation |
|
|
Pregnancy Risk
Factor |
|
C |
|
|
Adverse
Reactions |
|
1% to 10%: Local: Burning, stinging
<1%:
Central nervous system: Vertigo, seizures, psychoses, pseudotumor cerebri,
headache
Dermatologic: Stevens-Johnson syndrome, skin atrophy
Endocrine & metabolic: Cushing's syndrome, pituitary-adrenal axis
suppression, growth suppression
Gastrointestinal: Peptic ulcer, nausea, vomiting
Neuromuscular & skeletal: Muscle weakness, osteoporosis, fractures
Ocular: Cataracts, glaucoma |
|
|
Drug
Interactions |
|
Decreased effect: Silver, gentamicin, vaccines, toxoids |
|
|
Mechanism of
Action |
|
Interferes with bacterial growth by inhibiting bacterial folic acid synthesis
through competitive antagonism of PABA; decreases inflammation by suppression of
migration of polymorphonuclear leukocytes and reversal of increased capillary
permeability; suppresses the immune system by reducing activity and volume of
the lymphatic system |
|
|
Usual Dosage |
|
Children >2 months and Adults: Ophthalmic:
Solution: Instill 1-3 drops every 2-3 hours while awake |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
No effects or complications reported |
|
|
Patient
Information |
|
Eye drops will burn upon instillation; wait at least 10 minutes before using
another eye preparation; may sting eyes when first applied; do not touch
container to eye; ointment will cause blurred vision; notify physician if
condition does not improve in 3-4 days; may cause sensitivity to
sunlight |
|
|
Nursing
Implications |
|
Shake ophthalmic suspension before using |
|
|
Dosage Forms |
|
Ointment, ophthalmic:
AK-Cide®, Metimyd®,
Vasocidin®: Sulfacetamide sodium 10% and prednisolone
acetate 0.5% (3.5 g)
Blephamide®: Sulfacetamide sodium 10% and prednisolone
acetate 0.2% (3.5 g)
Cetapred®: Sulfacetamide sodium 10% and prednisolone
acetate 0.25% (3.5 g)
Suspension, ophthalmic: Sulfacetamide sodium 10% and prednisolone sodium
phosphate 0.25% (5 mL)
Suspension, ophthalmic:
AK-Cide®, Metimyd®: Sulfacetamide
sodium 10% and prednisolone acetate 0.5% (5 mL)
Blephamide®: Sulfacetamide sodium 10% and prednisolone
acetate 0.2% (2.5 mL, 5 mL, 10 mL)
Isopto® Cetapred®: Sulfacetamide
sodium 10% and prednisolone acetate 0.25% (5 mL, 15 mL)
Vasocidin®: Sulfacetamide sodium 10% and prednisolone
sodium phosphate: 0.25% (5 mL, 10 mL) |
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|